Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from the 2021 FDA approval of aducanumab (Aduhelm) and use of the accelerated approval pathway.
Terra Wonsettler, PharmD, MBA
Advertisement
Articles by Terra Wonsettler, PharmD, MBA
Advertisement
Latest Updated Articles
Cancer Drugs Speed to Accelerated Approvals, Then Hit the Brakes in Timely, Clinically Beneficial Confirmatory TrialsPublished: August 15th 2024 | Updated:
Whither CAR T? Will the FDA Being Under the Hood and the Availability of Bispecifics Make These Therapies Less Attractive?Published: June 12th 2024 | Updated:
The Dangerous Intersection of Breast Cancer and Cardiovascular Disease: A Call for Improved PreventionPublished: December 19th 2024 | Updated:
Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”Published: February 7th 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Reduction in Food Allergies Found After Guideline-Directed Early Peanut Exposure
2
Adding Radioligand Therapy Pluvicto to SOC Cuts Risk of Prostate Cancer Progression or Death 28%, but How Many Doses?
3
KEYNOTE-905 Paves the Way for Next Generation of MIBC Trials: Christof Vulsteke, MD, PhD
4
FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes
5
